Cellumen, RheoGene, Hurel, J&J, Evotec, Alnylam, MWG Biotech, Definiens, Chip-Man, Molecular Devices | GenomeWeb

Cellumen and RheoGene Enter Into Non-Exclusive Licensing Deal

Cellumen and RheoGene announced recently that they have entered into a non-exclusive commercial licensing agreement under which Cellumen will use RheoGene's RheoSwitch inducible gene regulation technology to develop cell biology screening products.

The products will include reagents for high content screening and stable cell lines. In addition, the companies will collaborate on the development and validation of mammalian cell lines to be used in Cellumen's cell biology profiling assays.

Get the full story with
GenomeWeb Premium

Only $95 for the
first 90 days*

A trial upgrade to GenomeWeb Premium gives you full site access, interest-based email alerts, access to archives, and more. Never miss another important industry story.

Try GenomeWeb Premium now.

Already a GenomeWeb Premium member? Login Now.
Or, See if your institution qualifies for premium access.

*Before your trial expires, we’ll put together a custom quote with your long-term premium options.

Not ready for premium?

Register for Free Content
You can still register for access to our free content.

In Science this week: metagenomic-based technique for determining protein structure, and more.

An academic laments the rise of narcissism in the sciences, the Guardian reports.

Outgoing FDA commissioner Robert Califf writes in an editorial that the agency can help boost innovation.

The Trump transition team has asked NIH Director Francis Collins to remain at his post, though it's unclear for how long that will be.